Literature DB >> 23831213

CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.

Miaotian Cai1, Francesco Bonella, Xuan He, Stephan U Sixt, Rafael Sarria, Josune Guzman, Ulrich Costabel.   

Abstract

BACKGROUND: CCL18 is a CC chemokine produced mainly by antigen-presenting cells, and is chemotactic predominantly for T-lymphocytes. CCL18 can stimulate pulmonary fibroblasts and increase the collagen production in vitro.
OBJECTIVES: This study aimed to compare the CCL18 levels in a variety of human biological fluids between various interstitial lung diseases (ILDs), and to reveal potential correlations with BAL cell differentials.
METHODS: Serum and bronchoalveolar lavage fluid (BALF) samples were collected from 199 patients with idiopathic pulmonary fibrosis (IPF), idiopathic non-specific interstitial pneumonia (iNSIP), respiratory bronchiolitis interstitial lung disease/desquamative interstitial pneumonia (RB-ILD/DIP), cryptogenic organizing pneumonia (COP), hypersensitivity pneumonitis (HP) or sarcoidosis. Alveolar macrophage (AM) culture was performed in 44 patients with IPF, iNSIP, COP, HP, sarcoidosis or non-ILDs. The CCL18 levels in serum, BALF and AM culture supernatant were measured with ELISA.
RESULTS: Both serum and BALF CCL18 levels in all ILDs were higher than in controls (all p < 0.005). In HP, CCL18 serum levels were the highest of all ILDs, and its BALF levels were significantly higher than in other ILDs except iNSIP. The BALF CCL18 levels markedly correlated with BAL cell differentials, especially with the percentage of BAL lymphocytes. In AM culture supernatant, the spontaneous CCL18 production was higher in HP and COP than in IPF and controls.
CONCLUSION: CCL18 levels in serum, BALF and AM culture supernatant are markedly increased in various inflammatory and fibrotic ILDs. However, the CCL18 level being highest in HP among the investigated ILDs suggests that CCL18 may be more profoundly involved in inflammatory immune responses.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AM; AMAC; ATS/ERS; AaO(2); American Thoracic Society/European Respiratory Society; BALF; CC chemokine ligand; CCL; CCL18; COP; DC-CK; DIP; DLco; ELISA; FEV; Fibrosis; HP; HRCT; Hypersensitivity pneumonitis; IFN; IIP; IL; ILD; IPF; Idiopathic pulmonary fibrosis; Inflammation; Interstitial lung disease; LPS; MIP; NSIP; PARC; RB-ILD; SaO(2); T-helper; TNF; Th; VC; alternative macrophage activation-associated CC chemokine; alveolar macrophage; alveolar-arterial PO(2) difference; bronchoalveolar lavage fluid; cryptogenic organizing pneumonia; dendritic cell-chemokine; desquamative interstitial pneumonia; diffusing capacity of the lung for carbon monoxide; enzyme-linked immunosorbent assay; forced expiratory volume; high-resolution computed tomography; hypersensitivity pneumonitis; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interferon; interleukin; interstitial lung disease; lipopolysaccharide; monocyte inflammatory protein; non-specific interstitial pneumonia; oxygen percent saturation (arterial); pulmonary and activity-regulated chemokine; respiratory bronchiolitis interstitial lung disease; tumor necrosis factor; vital capacity

Mesh:

Substances:

Year:  2013        PMID: 23831213     DOI: 10.1016/j.rmed.2013.06.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

1.  Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Masataka Kuwana; Ning Li; Michael D Roth; Julio Charles; Faye N Hant; Galina S Bogatkevich; Tanjina Akter; Grace Kim; Jonathan Goldin; Dinesh Khanna; Philip J Clements; Daniel E Furst; Robert M Elashoff; Richard M Silver; Shervin Assassi
Journal:  Arthritis Rheumatol       Date:  2019-11-01       Impact factor: 10.995

Review 2.  Molecular approach to the classification of chronic fibrosing lung disease-there and back again.

Authors:  Stijn E Verleden; Peter Braubach; Mark Kuehnel; Nicolas Dickgreber; Emily Brouwer; Pauline Tittmann; Florian Laenger; Danny Jonigk
Journal:  Virchows Arch       Date:  2020-11-09       Impact factor: 4.064

3.  Multiplatform Single-Cell Analysis Identifies Immune Cell Types Enhanced in Pulmonary Fibrosis.

Authors:  Ana P M Serezani; Bruno D Pascoalino; Julia M R Bazzano; Katherine N Vowell; Harikrishna Tanjore; Chase J Taylor; Carla L Calvi; A Scott McCall; Matthew D Bacchetta; Ciara M Shaver; Lorraine B Ware; Margaret L Salisbury; Nicholas E Banovich; Peggy L Kendall; Jonathan A Kropski; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2022-07       Impact factor: 7.748

4.  CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN.

Authors:  Silke R Brix; Gesa Stege; Erik Disteldorf; Elion Hoxha; Christian Krebs; Sonja Krohn; Benjamin Otto; Kristin Klätschke; Elisabeth Herden; Felix Heymann; Sergio A Lira; Frank Tacke; Gunter Wolf; Martin Busch; Wolfram J Jabs; Fedai Özcan; Frieder Keller; Joachim Beige; Karl Wagner; Udo Helmchen; Mercedes Noriega; Thorsten Wiech; Ulf Panzer; Rolf A K Stahl
Journal:  J Am Soc Nephrol       Date:  2015-03-11       Impact factor: 10.121

Review 5.  The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Authors:  Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi
Journal:  Lancet Respir Med       Date:  2016-12-06       Impact factor: 30.700

6.  Silencing XIST mitigated lipopolysaccharide (LPS)-induced inflammatory injury in human lung fibroblast WI-38 cells through modulating miR-30b-5p/CCL16 axis and TLR4/NF-κB signaling pathway.

Authors:  Jiahui Xu; Honggui Li; Ying Lv; Chang Zhang; Yiting Chen; Dezhao Yu
Journal:  Open Life Sci       Date:  2021-02-06       Impact factor: 0.938

Review 7.  Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.

Authors:  Alsya J Affandi; Timothy R D J Radstake; Wioleta Marut
Journal:  Semin Immunopathol       Date:  2015-07-14       Impact factor: 9.623

Review 8.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

9.  Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.

Authors:  Kosuke Hamai; Hiroshi Iwamoto; Nobuhisa Ishikawa; Yasushi Horimasu; Takeshi Masuda; Shintaro Miyamoto; Taku Nakashima; Shinichiro Ohshimo; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori; Nobuoki Kohno
Journal:  Dis Markers       Date:  2016-05-17       Impact factor: 3.434

10.  Upregulation of receptor tyrosine kinase-like orphan receptor 2 in idiopathic pulmonary fibrosis.

Authors:  Ji-Hye Son; Jong-Uk Lee; Susie Chin; Eun-Suk Go; Jai-Seong Park; Hwa-Kyun Shin; Hun Soo Chang; Jong-Sook Park; Choon-Sik Park
Journal:  Korean J Intern Med       Date:  2020-09-21       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.